Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton, PA, July 11, 2023 – In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata (AA). At one-year post approval, perceptions of the […]
Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients
Lack of vision improvement, amongst other efficacy concerns, as well as potential for conversion to neovascular age-related macular degeneration are among core barriers limiting Syfovre uptake, according to Spherix Global Insights. EXTON, Pa., June 28, 2023 –With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy […]
Nearly One Year Post-Launch Biogen & Coherus Biosciences’ Ranibizumab Biosimilars Have Yet to Make a Splash in Their Respective Retina Markets
Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to be cooling, according to a recent analysis from Spherix Global Insights. EXTON, Pa., June 23, 2023 — Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars Today and […]
Don’t Mess with Success: U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights
Adalimumab biosimilars hold potential to grow the overall biologic-treated population, but only if the cost savings translate to patients and practices. EXTON, Pa., June 7, 2023 — Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global Insights, even the first to market advantage can’t […]
Genentech’s Vabysmo Boasts Increasingly Favorable Perceptions Among Ophthalmologists for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, According to Spherix Global Insights
Despite Vabysmo’s positive first impressions, the race is about to heat up with the widely anticipated FDA approval of Regeneron’s 8mg aflibercept potentially around the corner. EXTON, Pa., June 7, 2023 — Genentech’s Vabysmo got an 18-month head start over Regeneron’s high dose Eylea (8mg aflibercept), but that lead time may be coming to a […]
Spherix Global Insights Launches New Portal Providing Seamless Client Access to Subscribed Data and Insights
Online platform underscores Spherix’s commitment to innovation by providing dynamic solutions generated from the company’s comprehensive insights library of reports & dashboards Exton, PA., May 19, 2023 – Spherix Global Insights, a leading provider of market research, business intelligence and advisory services to the global life sciences industry, announced today the global launch of its […]
Roche’s Genentech debuts first consumer effort for diabetes and age-related eye disease drug
Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped screen, stepping through into different beach, gardening and hiking scenarios. The campaign theme “Open Up Your World” mirrors her narration that the eye medication can improve eyesight and “open up” favorite activities for people with […]
At Eighteen Months Post-Launch, Impel’s Trudhesa Has Struggled to Keep Up with Pfizer’s Nurtec ODT and AbbVie’s Ubrelvy, According to Spherix Global Insights
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it exceeding the Eli Lilly offering. Exton, PA., April 14, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of […]
Imaging required to monitor effects of new Alzheimer’s drug could inhibit its uptake
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the drug’s effect on patients could limit its uptake. In January 2023, Eisai/Biogen’s Leqembi—a drug shown to reduce clinical decline by up to 27% in patients with Alzheimer’s—was given accelerated approval by the U.S. Food and Drug […]
Eisai’s Alzheimer’s drug Leqembi gaining ground with US neurologists, but most waiting on full approval: Spherix
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. That’s according to a new survey and report out by drug launch analyst Spherix Global Insights, which in March asked 73 neurologists working in […]
